Compound class:
Synthetic organic
Comment: Compound 6li is reported as an orally bioactive inhbitor of AXL receptor tyrosine kinase [1]. It was designed for antitumour potential.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Strong binding to a number of other receptor tyrosine kinases was detected in a kinase selectivity profile study using 6li at 100nM (which is equivalent to >350-fold its Kd of 0.26 nM) [1]. Compound 6li exhibits in vivo antitumour efficacy in a xenograft model of metastatic murine breast cancer. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|